共查询到20条相似文献，搜索用时 31 毫秒
1.
J. Encaoua R. Abgral C. Leleu O. El Kabbaj P. Caradec D. Bourhis O. Pradier U. Schick 《Cancer radiothérapie》2017,21(4):267-275
Purpose
To study the impact on radiotherapy planning of an automatically segmented target volume delineation based on (18F)-fluorodeoxy-D-glucose (FDG)-hybrid positron emission tomography–computed tomography (PET-CT) compared to a manually delineation based on computed tomography (CT) in oesophageal carcinoma patients.Methods and materials
Fifty-eight patients diagnosed with oesophageal cancer between September 2009 and November 2014 were included. The majority had squamous cell carcinoma (84.5 %), and advanced stage (37.9 % were stade IIIA) and 44.8 % had middle oesophageal lesion. Gross tumour volumes were retrospectively defined based either manually on CT or automatically on coregistered PET/CT images using three different threshold methods: standard-uptake value (SUV) of 2.5, 40 % of maximum intensity and signal-to-background ratio. Target volumes were compared in length, volume and using the index of conformality. Radiotherapy plans to the dose of 50 Gy and 66 Gy using intensity-modulated radiotherapy were generated and compared for both data sets. Planification target volume coverage and doses delivered to organs at risk (heart, lung and spinal cord) were compared.Results
The gross tumour volume based manually on CT was significantly longer than that automatically based on signal-to-background ratio (6.4 cm versus 5.3 cm; P < 0.008). Doses to the lungs (V20, Dmean), heart (V40), and spinal cord (Dmax) were significantly lower on plans using the PTVSBR. The PTVSBR coverage was statistically better than the PTVCT coverage on both plans. (50 Gy: P < 0.0004 and 66 Gy: P < 0.0006).Conclusion
The automatic PET segmentation algorithm based on the signal-to-background ratio method for the delineation of oesophageal tumours is interesting, and results in better target volume coverage and decreased dose to organs at risk. This may allow dose escalation up to 66 Gy to the gross tumour volume. 相似文献2.
3.
S. Lévy S. Chapet N. Scher K. Debbi A. Ruffier G. Bernadou Y. Pointreau G. Calais 《Cancer radiothérapie》2017,21(8):759-765
4.
H. Carette J.-C. Faivre J. Salleron A.-S. Baumann L. Uwer C. Clément-Duchêne J.-M. Vignaud I. Petit J. Siat A. Tiotiu V. Beckendorf 《Cancer radiothérapie》2017,21(8):774-783
Purpose
Prophylactic radiotherapy to prevent procedure-tracts metastases from malignant pleural mesothelioma remains controversial and clinical practice varies. The purpose was to assess the efficacy of local radiotherapy in a single fraction of 10 Gy in preventing malignant seeding at intervention pleural site in patients with malignant pleural mesothelioma.Material and methods
This is a retrospective cohort study, including patients with histological confirmed malignant pleural mesothelioma treated by prophylactic irradiation to prevent interventional site metastases with a unique fraction of 10 Gy with 6 to 18 MeV, from January 1990 to December 2013 in the institut de cancérologie de Lorraine (Nancy, France).Results
Ninety-one patients were treated by irradiation in intervention site, involving 120 intervention pleural sites, 91 thoracoscopies, 17 thoracotomies with chest drain and 12 CT or ultrasound guided needle biopsies. The median follow-up was 7 months (interquartile between 3 and 15 months). The overall survival was 43.5% at 12 months. The local progression free survival was 43.7% at 12 month. The incidence of local recurrence was 8% at 12 months. The median interval from radiotherapy to local recurrence was 4 months (2; 32). No grade II or higher toxicity was observed.Conclusion
Irradiation of pleural intervention sites with a single fraction of 10 Gy is effective, well tolerated, simple, fast and cost effective. 相似文献5.
A. Keller M. Doré D. Antoni I. Menoux F. Thillays J.B. Clavier G. Delpon D. Jarnet C. Bourrier F. Lefebvre S. Chibbaro I. Darié F. Proust G. Noël 《Cancer radiothérapie》2017,21(5):377-388
Purpose
To investigate the factors that potentially lead to brain radionecrosis after hypofractionated stereotactic radiotherapy targeting the postoperative resection cavity of brain metastases.Methods and materials
A retrospective analysis conducted in two French centres, was performed in patients treated with trifractionated stereotactic radiotherapy (3 × 7.7 Gy prescribed to the 70% isodose line) for resected brain metastases. Patients with previous whole-brain irradiation were excluded of the analysis. Radionecrosis was diagnosed according to a combination of criteria including clinical, serial imaging or, in some cases, histology. Univariate and multivariate analyses were performed to determine the predictive factors of radionecrosis including clinical and dosimetric variables such as volume of brain receiving a specific dose (V8 Gy–V22 Gy).Results
One hundred eighty-one patients, with a total of 189 cavities were treated between March 2008 and February 2015. Thirty-five patients (18.5%) developed radionecrosis after a median follow-up of 15 months (range: 3–38 months) after hypofractionated stereotactic radiotherapy. One third of patients with radionecrosis were symptomatic. Multivariate analysis showed that infra-tentorial location was predictive of radionecrosis (hazard ratio [HR]: 2.97; 95% confidence interval [95% CI]: 1.47–6.01; P = 0.0025). None V8 Gy–V22 Gy was associated with appearance of radionecrosis, even if V14 Gy trended toward significance (P = 0.059).Conclusion
Analysis of patients and treatment variables revealed that infratentorial location of brain metastases was predictive for radionecrosis after hypofractionated stereotactic radiotherapy for postoperative resection cavities. 相似文献6.
Abdel-Rahman N. Zekri Enas R. El-Sisi Zeinab F. Abdallah Alaa Ismail Ahmed Barakat Barakat 《Journal of the Egyptian National Cancer Institute》2017,29(1):19-24
Aim
Identifying the genetic expression profile of CD133+ cells from HCC patients compared to CD133+ cells from healthy volunteers that may contribute in hepatocarcinogenesis process.Method
Circulating CD133+ cells were sorted from the peripheral blood of HCC patients as well as from healthy volunteers using magnetic activated cell sorting. The differential expression profile of stem cell related genes was performed using the Stem Cell PCR profiling assay.Results
Data analysis of stem cells related genes in CD133+ cells of the HCC group compared to the control group showed that; CCND2, COL1A1, CTNNA1, DLL3, JAG1, KRT15, MYC, NOTCH2, T and TERT were up-regulated (fold change = 80, 68.6, 6.67, 7.22, 3.8, 15.2, 14.5, 105.6, 26.6 and 99 respectively while only CD3D was down-regulated (fold change = 0.055) in HCC patients. However, after application of Beferroni correction to adjust P-value; KRT15 was the only gene that was significantly over expressed in CD133+ cells of HCC compared to control group (P-value = 0.012).Conclusion
KRT15 can be used to differentiate between circulating CD133+ cells from HCC group and control group. However, further study may be needed to confirm on the protein level. 相似文献7.
Purpose
To evaluate local control and adverse effects after postoperative hypofractionated stereotactic radiosurgery in patients with brain metastasis.Methods
We reviewed patients who had hypofractionated stereotactic radiosurgery (7.7 Gy × 3 prescribed to the 70% isodose line, with 2 mm planning target volume margin) following resection from March 2008 to January 2014. The primary endpoint was local failure defined as recurrence within the surgical cavity. Secondary endpoints were distant failure rates and the occurrence of radionecrosis.Results
Out of 95 patients, 39.2% had metastatic lesions from a non-small cell lung cancer primary tumour. The median Graded Prognostic Assessment score was 3 (48% of patients). One-year local control rates were 84%. Factors associated with improved local control were no cavity enhancement on pre-radiation MRI (P < 0.00001), planning target volume less than 12 cm3 (P = 0.005), Graded Prognostic Assessment score 2 or above (P = 0.009). One-year distant cerebral control rates were 56%. Thirty-three percent of patients received whole brain radiation therapy. Histologically proven radionecrosis of brain tissue occurred in 7.2% of cases. The size of the preoperative lesion and the volume of healthy brain tissue receiving 21 Gy (V21) were both predictive of the incidence of radionecrosis (P = 0.010 and 0.036, respectively).Conclusion
Adjuvant hypofractionated stereotactic radiosurgery to the postoperative cavity in patients with brain metastases results in excellent local control in selected patients, helps delay the use of whole brain radiation, and is associated with a relatively low risk of radionecrosis. 相似文献8.
G.A. Turgeon L. Souhami N. Kopek V. Hirsh L. Ofiara S.L. Faria 《Cancer radiothérapie》2017,21(2):89-98
Purpose
Many Canadian institutions treat limited-disease small cell lung cancer with 40 Gy in 15 fractions delivered once-a-day in 3 weeks concomitantly with chemotherapy. This regimen is convenient and seems to be effective. Here, we report and compare with a literature review the outcomes of patients with limited-stage small cell lung cancer treated in our institution with this hypofractionated regimen.Patients and methods
From January 2004 to December 2012, patients with limited-stage small cell lung cancer treated curatively with platinum-based chemotherapy and concurrent thoracic radiotherapy at a dose of 40 Gy in 16 fractions once-a-day were eligible for this review.Results
Sixty-eight patients fit the analysis criteria, including ten patients with small pleural effusion. The median age was 66 years old. After a median follow-up of 77 months for those alive, the median survival was 28 months. At 3 and 5 years respectively, the locoregional control rates were 67 and 64%, while the overall survival rates were 40 and 35%. Prophylaxis cranial irradiation was delivered to 68% of the patients. Grade 2 and 3 acute esophagitis occurred in respectively 49 and 9% of the patients. There was no grade 4 radiation-induced toxicity. All patients, except for one, completed their thoracic irradiation course without interruption.Conclusion
Once-a-day hypofractionated radiation with concurrent chemotherapy followed by prophylactic cranial irradiation is a practical regimen. Based on our experience and the published literature, it appears to be similarly effective as regimens using twice-daily fractionation in 3 weeks, or once-daily in 6 to 7 weeks with higher radiotherapy doses. Further prospective comparisons of hypofractionation with the current recommendations are needed. 相似文献9.
Z. Ajgal S. de Percin V. Diéras J.Y. Pierga F. Campana A. Fourquet Y.M. Kirova 《Cancer radiothérapie》2017,21(2):114-118
Background and purposes
We evaluate the early toxicity of concurrent use of radiotherapy, pertuzumab and trastuzumab in patients with HER2-positive metastatic or locally recurrent unresectable breast cancer.Patients and methods
A retrospective study was performed in a population of 23 consecutive patients between 2013 and 2015. Radiotherapy was performed on the chest area or metastatic sites during maintenance with pertuzumab and trastuzumab after six cycles of pertuzumab, trastuzumab and docetaxel. Toxicity was assessed according to the National Cancer Institute Common Toxicity Criteria version 4.Results
Irradiation volumes were whole breast (8 patients) and chest wall (9 patients) at 50 Gy in 25 fractions, the supraclavicular nodes (16 patients), the axillary area (nine patients) and the internal mammary nodes (9 patients) at 46 Gy in 23 fractions. For five patients, radiotherapy was palliative: bone irradiation (4 patients), whole brain radiotherapy (one patient). Median follow-up was 12.6 months (range: 6.1–21.6 months) since the start of pertuzumab and trastuzumab. One patient presented an asymptomatic decrease of left ventricular ejection fraction below 50%. No symptomatic cardiac events were reported. Two patients presented asymptomatic grade I radiation pneumonitis. Acute skin toxicity was grade III (one patient), grade II (6 patients), and grade I (5 patients). There were two grade II esophagitis.Conclusion
Combination of pertuzumab, trastuzumab and radiotherapy was well tolerated, which should be confirmed by the results of larger studies. 相似文献10.
M. Kruszyna S. Adamczyk A. Skrobała M. Skórska W. Suchorska K. Zaleska A. Kowalik W. Jackowiak J. Malicki 《Cancer radiothérapie》2017,21(5):345-351
Purpose
To measure out-of-field doses in a phantom model to better quantify this radiation.Material and methods
The individual contribution of photons and neutrons to the total out-of-field dose for 6 MV and 20 MV photons at open beam were measured in a purpose-designed water phantom. Radiation doses were measured at seven separate points (P1–P7) in the phantom with thermoluminescent detectors (TLD 100, 600, and 700) and GAFchromic? EBT films.Results
At a prescribed dose of 75 Gy to the isocentre, the photon dose level in the close-to-field area (P2) ranged from 2.0–2.5 Gy for 6 MV and 1.5–2.0 Gy for 20 MV; the total out-of-field doses at P2 and P7, respectively, were estimated to be as follows: for 6 MV: TLD 100 (< 3.23% and < 0.14%); radiochromic film (< 2.52% and < 0.03%); and for 20 MV: TLD 100 (< 2.94% and < 0.78%); TLD 700 (< 2.02% and < 0.14%); and radiochromic film (< 1.73% and < 0.01%). Although the dose decreased rapidly as the distance from the central beam axis increased, even distant doses could be as high as several centigrays. The neutron dose for 20 MV photons at a distance of 25 cm from the isocentre was 4.0 mSv/Gy.Conclusion
Our results show that in the close-to-field area, the dose level could be as high as 1.5 Gy assuming a prescribed dose of 75 Gy to the isocentre. By contrast, the doses delivered to more distant areas from the planning target volume were much lower (centigrays). These findings show that both 6 MV and 20 MV photons could produce dosimetrically important dose levels outside of the field. The data reported here may be of value to study the potential impact of even very low doses of radiation on human tissues. 相似文献11.
Purpose
To estimate the long-term risk of second malignancies after breast cancer treatment in a large homogeneous cohort from a single institution.Patients and methods
All patients in this study were treated for non-metastatic breast cancer at the Curie institute, Paris, between 1981 and 2000. We calculated the cumulative incidence of second malignancies and the risk of developing each type of second malignancies over a period of 10 to 15 years. The observed crude incidence rates in the entire patient population were then compared to the expected incidence in the general population of French women, as provided by age-standardized data. A standardized incidence ratio (SIR) was calculated for all second malignancies. We also calculated second malignancies standardized incidence ratios for patients who underwent adjuvant therapy for breast cancer.Results
The study cohort included a total of 17,745 women. The median follow-up since diagnosis was 13.4 years (range: 2–29 years). The 15-year cumulative incidence of second malignancies was 1.807 per 100,000 (CI 1.729–1.884). A total of 2370 second malignancies were observed during follow-up, 2010 in the radiotherapy arm and 360 in the no radiotherapy arm (relative risk [RR] 1.15 [1.03–1.28], P = 0.0134). Crude incidence rates were significantly higher in our cohort than in the general population for contralateral breast cancer (SIR 2.96 [confidence interval (CI) 2.82–3.12], P < 0.0001), sarcomas (SIR 8.48 [CI 6.41–11.22], P < 0.0001), leukaemia (SIR 2.37 [CI 1.85–3.04], P < 0.0001), lung cancer (SIR 1.39 [CI 1.13–1.72], P < 0.0022) and gynaecological cancer (SIR 1.31 [CI 1.15–1.50], P = 0.0001). Among patients treated for breast cancer, those who received radiotherapy was associated with an excess risk of sarcoma as compared to those have not had (RR 5.59 [CI 1.35–23.17], P < 0.001).Conclusions
Women treated for breast cancer had a significantly increased risk of several kinds of second malignancies compared to the general population. 相似文献12.
Emad Moussa Manal Zamzam Ahmed Kamel Zeinab Salah Iman Attia Lina Gaber Ranin Soliman Sameera Ezzat 《Journal of the Egyptian National Cancer Institute》2017,29(1):53-56
Introduction
Anthracycline chemotherapy contributes to improved outcomes in Ewing sarcoma; however, the most feared complication is cardiotoxicity. Echocardiograms were routinely used to monitor cardiac function after anthracycline treatment. Nevertheless, indices chosen to assess cardiac toxicity vary significantly among different centers, and no uniform protocol has been accepted as ideal.Methods
This retrospective study included children with Ewing sarcoma treated at Children’s Cancer Hospital Egypt over 4 years. All echocardiograms and related clinical assessments were reviewed.Results
In total, 149 patients (median age 11 years; range 1–18 years) were included. Although all patients had a reduced ejection fraction compared with their baseline echocardiogram, only 39 patients developed cardiotoxicity (26%): 43% acute-onset, 36% chronic early-onset, and 21% chronic late-onset. There were no statistically significant association between the frequency of myocardial dysfunction and risk factors, including age, sex, follow-up duration, cumulative doxorubicin dose, and mediastinal irradiation. Over one-third (39%) of the patients with cardiac toxicity regained normal cardiac parameters, whereas seven patients died of acute cardiac toxicity.Conclusion
The routine use of echocardiography to screen for anthracycline-induced cardiac toxicity before and during chemotherapy identified myocardial dysfunction. Early medical intervention can improve cardiac parameters. Improved screening techniques with better sensitivity and predictability are needed. 相似文献13.
C. Gamelon-Bénichou S. Oldrini C. Charra-Brunaud G. Vogin J. Salleron D. Peiffert 《Cancer radiothérapie》2017,21(3):171-179
Purpose
To evaluate prospectively chronic gastrointestinal toxicity in patients with cervical cancer treated with conventional irradiation or with intensity-modulated irradiation (IMRT).Patients and methods
Between June 2005 and September 2013, 109 patients underwent external radiotherapy followed by brachytherapy for cervical cancer at the “Institut de Cancérologie de Lorraine”. Each patient receiving IMRT was paired with a patient receiving conventional radiotherapy on the following criteria: concomitant chemotherapy, additional nodal dose, treatment of para-aortic lymph node area, age. The toxicity collection was prospective using the RTOG scale. The main objective was to compare the incidence of gastrointestinal toxicity chronic between the two groups. In a second time, the influence of dosimetric parameters on chronic GI toxicity was investigated. Comparisons of acute toxicity, chronic genitourinary toxicities, overall survival, disease-free survival were secondary objectives.Results
Sixty-six patients were able to be matched. Overall survival at 36 months was 71% in the conventional radiotherapy group against 73% in the IMRT group (P = 0.54). There was no significant difference between the two groups in terms of digestive chronic toxicity (P = 0.17), nor in terms acute gastrointestinal toxicities (P = 0.6445) and genitourinary (P = 0.5724). IMRT spared significantly small bowel (P = 0.0006) and rectum (P = 0.0046) from 30 Gy dose, and bladder from 45 Gy (P < 0.001). The incidence of genitourinary toxicity was significantly different between the two groups (P = 0.03) in favor of conventional radiotherapy.Conclusion
Our study does not seem to show significant difference in the occurrence of chronic gastrointestinal toxicities between the two groups. Clinical efficacy seems comparable. Larger studies with longer follow-up period should be conducted. 相似文献14.
R. Sun X. Cuenca R. Itti S. Nguyen Quoc J.-P. Vernant J.-J. Mazeron C. Jenny M. Chea 《Cancer radiothérapie》2017,21(5):365-372
Purpose
Dynamic conformal radiotherapy with helical TomoTherapy® (HT) offers a more quantitative paradigm for total body irradiation. Treatment planning, delivery, dose verification of the first French experiences of total body irradiation using helical TomoTherapy® are presented.Materials and methods
Patients planned for total body irradiation at our institution from February 2012 to May 2013 were reported. Total body irradiation consisted in a single fraction of 2 Gy. Planning target volume was divided in two due to the limited translation length of the table. Delivery quality assurance was performed with cylindrical phantom, ionization chamber and films. Thermoluminescent dosimeters and radiochromic films were used for in vivo dosimetry and junction region heterogeneity assessment.Results
Six patients were included. One finally did not receive the treatment but dosimetric data were analyzed. Planned V95% was covered by D95% and V2% did not exceed D107% for five of the six patients. The mean relative difference between measured and calculated absolute dose of the Delivery quality assurance was always less than 2.5% (mean value ± SD: 1% ± 0.67%). Gamma index (3%; 3 mm) was less than 1 for at least 93% of the points (value ± SD: 97.4 ± 1.6% and 96.6 ± 2.5% for upper and lower part of treatment respectively). Difference between in vivo measured and calculated dose was above 5% for only two out of 15 points (maximum: 10.2%, mean: 0.73 ± 4.6%). Junction region heterogeneity was in average 5.8 ± 1%. The total treatment session of total body irradiation lasted 120 min, with a mean beam on time of 17.2 ± 0.6 and 11.2 ± 1.6 min for upper and lower part of the body respectively.Conclusion
Total body irradiation using helical TomoTherapy® guaranteed high dose homogeneity throughout the body and dose verification was achievable, showing small difference between planned and delivered doses. 相似文献15.
C. Benhaïm G. Loos J.L. Achard L. Berger C. Caillé T. Frédéric-Moreau J. Biau M. Lapeyre 《Cancer radiothérapie》2017,21(1):28-33
Purpose
Intensity modulated radiotherapy for prostate cancer involves daily monitoring of the positioning of the prostate, possible with cone beam CT (CBCT). It allows increased accuracy compared to readjustments but induces an increase in the time dedicated to these medical checks. The aim of the study was to evaluate the possibility of delegation of this task to the radiation therapists by comparing their readjustments to the doctors.Patients and methods
Five consecutive patients treated with radiation for prostate cancer (76 Gy) were analysed. All had a daily CBCT for position control. The movements of the prostate relative to the bony part, the positional variations of the prostate measured by the radiation therapists and the doctors and medical time required to analyse imagery (filling of the rectum and bladder and perform a recalibration) were measured.Results
One hundred seventy-six CBCT were analysed or 980 steps in the three axes. The movements of the prostate relative to bony part were respectively at least 5 mm in 19%, 7% and 3% in the anterior–posterior, upper–lower and right–left axes. Changes readjustments between radiation therapists and doctors were in 95% of cases at the most 4 mm in the anterior–posterior and upper–lower axis, and 3 mm in the left–right axis. The time for medical use of the CBCT averaged 8 min 40 [4 to 22 min].Conclusion
The daily readjustment on the prostate using CBCT may be delegated to radiation therapists with acceptable concordance of less than 4 mm for 95% of measurements. An initial and ongoing training will ensure treatment safety. 相似文献16.
Purpose
This retrospective study aimed to determine whether the maximum standardised uptake value (SUVmax) can predict local tumour control in early glottic cancer (Tis, T1, and T2).Patients and methods
Fifty-nine patients treated with definitive radiotherapy for early glottic cancer between 2003 and 2011 were enrolled. We evaluated the SUVmax in the region of interest around the original tumour site. Local tumour control and survival were estimated using Kaplan-Meier curves. Receiver operating characteristic curves were used to assess the optimal SUVmax cut-off for predicting local control.Results
As determined by laryngoscopy, all patients achieved a complete response. Eleven patients experienced local recurrence, while no distant metastasis occurred. One patient died due to local recurrence, while five lost their larynxes. The median follow-up was 61.5 (range: 6.2–123.4) months. The five-year local progression-free survival was 84.7%, and larynx preservation was possible in 89.6% of cases. The median SUVmax was 2.2. The optimal SUVmax for predicting local tumour control was identified as 3.4. Patients with glottic cancers with an SUVmax > 3.4 showed a significantly lower local progression-free survival rate than those with tumours with an SUVmax < 3.4 (five-year local progression-free survival rate: 53.4% vs. 95.4%, P < 0.01). Multivariate analysis confirmed that a high SUVmax was an independent predictive factor for local progression-free survival (P = 0.006).Conclusion
The use of (18F)-fluorodeoxyglucose-positron emission tomography for evaluation of the SUVmax is useful to predict local progression-free survival in patients with early glottic cancer treated by radiation. Early glottic cancer with a high SUVmax may require aggressive local treatment and careful surveillance. 相似文献17.
18.
Pramod K. Julka Daya Nand Sharma Renu Madan Supriya Mallick Rony Benson Haresh Kunhi P Subhash Gupta Goura K. Rath 《Journal of the Egyptian National Cancer Institute》2017,29(1):47-51
Background/purpose
Lung cancer is the commonest malignancy and the most common cause of cancer related mortality in males worldwide. Non-small cell lung cancer (NSCLC) is the commonest histology while small cell lung cancer (SCLC) contributes to only 15% of all cases of lung cancer. This report intended to present the patterns of care, survival outcomes and prognostic factors of SCLC treated in a tertiary care institute.Results
A total of 85 patients of SCLC were registered in radiotherapy unit I during the period January, 2005 to December, 2012. The median age of the cohort was 56.5 years (95% CI 34–72). The majority of the patients were male with a male:female ratio of 6.7:1. Sixty eight percent of the patients were smokers. Sixty percent patients presented with extensive stage disease. Radiotherapy (RT) was used in 76% of the patients while chemotherapy was used in 75% of the patients. Platinum Etoposide was the most common regimen which was used in 70% of the patients who received chemotherapy. The median progression free survival (PFS) of the entire cohort was 11.4 months (95% CI 9.11–13.58 months). Stage, performance status, and use of chemotherapy were found to be significant factors affecting survival outcome in patients with SCLC.Conclusion
The pattern of care and survival outcomes in the present study parallels that of the various published retrospective reviews. Basic research and development of targeted agents may be the way forward in improving the outcome of patients with SCLC. 相似文献19.
L. Ghorbal F. Elloumi W. Siala A. Khabir A. Ghorbel M. Frikha J. Daoud 《Cancer radiothérapie》2017,21(1):40-44
Purpose
Retrospective analysis of clinical aspects and therapeutic results of nasopharynx cancer local failures.Patients and methods
Forty patients with local failure with or without nodal involvement of nasopharyngeal carcinoma were treated between 1993 and 2013. Reirradiation of nasopharynx was delivered at the dose of 60 Gy. Platinum-based chemotherapy was indicated in case of locally advanced disease and/or associated nodal failure.Results
The mean age at diagnosis of primitive tumour was 41.9 years (26–67 years). The mean time of relapse occurrence was 31.7 months (6–104 months). Sixty five percent of failures were confined to the nasopharynx. Nodal failure was seen in 14 cases. Twenty-eight patients had chemotherapy. Twenty-five patients had reirradiation of nasopharynx. Mean follow-up was 98 months (12–191 months). Fourteen patients were still alive and in complete remission. Five-year survival was 40.7%. Xerostomia was the most frequent late toxicity. No haemorrhage was seen.Conclusion
Reirradiation is the mainstay treatment of nasopharyngeal local failure. Late toxicity seems to decrease with novel techniques of reirradiation. 相似文献20.
Wiebke Neumann Florian Lietzmann Lothar R. Schad Frank G. Zöllner 《Zeitschrift für medizinische Physik》2017,27(2):124-131